Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ...

Regeneron国际科学与工程大奖赛 (Regeneron ISEF)是由美国Society for ...

周二，UBS分析师重申了对Regeneron制药公司股票 (NASDAQ: REGN)的中性评级，维持633.00美元的目标价。此决定是在Regeneron肥胖症治疗管线的最新进展后作出的。该股目前交易价格接近其52周低点481.58美元，过去一周内股价急剧下跌18.6%。 InvestingPro 分析表明，该股目前被低估，分析师设定的目标价范围从535美元到950美元不等。

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler presentations and more severe and prolonged lesions compared to patients with ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

根据许可协议，许可人将授予被许可人开发、生产及商业化HS-20094 (该产品)的全球独占许可 ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

周一，Truist Securities分析师重申了对Regeneron制药公司 (NASDAQ: REGN)股票的买入评级，维持940美元的目标价。此决定是在itepekimab治疗慢性阻塞性肺病 (COPD)的第三期临床试验结果喜忧参半之后做出的，这导致该公司股票在过去一周内大幅下跌16.7%。根据 InvestingPro ...

美通社消息，翰森制药集团有限公司 宣布与Regeneron Pharmaceuticals, Inc.订立许可协议，授予Regeneron开发、生产及商业化HS-20094的全球独占许可（不含中国内地、香港、澳门）。 HS-20094是一款在研GLP ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

截至2025年6月2日收盘，翰森制药 ...